Table 1.
Demographic characteristics of study participants.
| Characteristic | Minocycline (n = 12) |
Placebo (n = 9) |
P value |
|---|---|---|---|
| Sex | 0.66a | ||
| Female | 8 | 7 | |
| Male | 4 | 2 | |
| Translocator protein genotypeb | 1.000a | ||
| High-affinity binders | 9 | 6 | |
| Mixed-affinity binders | 3 | 3 | |
| Age, years, mean (SD) | 36.5 (13.4) | 36.9 (12.0) | 0.94c |
| Body mass index, mean (SD) | 24.7 (2.7) | 25.1 (4.3) | 0.76c |
| Level of education, years, mean (SD) | 17.3 (4.0) | 15.3 (2.3) | 0.22c |
| HDRS scored | 20.2 (3.5) | 20.3 (6.1) | 0.94c |
| Age at first MDE, years, mean (SD) | 14.8 (6.3) | 20.4 (11.0) | 0.15c |
| Number of MDEs, mean (SD) | 5.4 (3.4) | 8.0 (5.6) | 0.21c |
| Number of previous antidepressant treatment, mean (SD)e | 5.0 (3.4) | 5.6 (2.0) | 0.67c |
| Previous antidepressant treatment, years, mean (SD) | 9.2 (7.1) | 7.3 (6.5) | 0.53c |
| Years of untreated major depressive disorder, mean (SD) | 11.9 (10.5) | 8.9 (8.2) | 0.49c |
| Number of previous suicide attempts, mean (SD) | 0.3 (0.6) | 0.4 (0.7) | 0.52c |
HDRS Hamilton Depression Rating Scale, MDE major depressive episode, PET positron emission tomography, SD standard deviation, [18F]FEPPA, F 18-labeled N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide).
aFisher’s exact test.
brs6971 genotype influences the binding of second-generation radiotracer ligands including [18F]FEPPA.
cUnivariate analysis of variance.
dScore derived at baseline PET scan. At the time of initial screening, HDRS score was 19 or greater but with ongoing variation in severity of illness, five participants had HDRS below 19 at the time of the first PET scan.
ePrevious treatments included quetiapine, repetitive transcranial magnetic stimulation, magnetic seizure therapy, and electroconvulsive therapy.